Form 4: Boston Scientific Director Receives Restricted Stock Grant

Boston Scientific's new director, Christophe Pierre Weber, received restricted stock grants totaling 879 shares as part of his compensation package.

Summary

• Christophe Pierre Weber, a newly appointed Director at Boston Scientific Corp (BSX), acquired 879 shares of common stock through restricted stock grants.
• The first grant consisted of 556 shares of restricted stock, valued at approximately $42,419.50, representing a prorated portion of the annual equity award for non-employee directors.
• This equity award is part of the company's non-employee director compensation program, with the full annual equity award valued at $215,000.
• The second grant involved 323 shares of restricted stock, valued at approximately $24,662.50, issued in lieu of 100% of the prorated yearly cash compensation.
• This cash compensation component is also part of the non-employee director compensation program, with the full annual cash retainer valued at $125,000.
• Both grants were made on March 2, 2026, and the restricted stock vests in full upon the date of the Company's 2026 annual meeting of stockholders.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard director compensation practices that align management interests with shareholders, without indicating any significant operational or financial changes.

Positives

• The restricted stock grants align the interests of the new director, Christophe Pierre Weber, with those of shareholders, as his compensation is tied to the company's stock performance.
• The compensation structure, including both equity and cash components, is part of a defined non-employee director compensation program, indicating structured corporate governance.

Future Outlook

The restricted stock grants are set to vest in full upon the Company's 2026 annual meeting of stockholders, indicating a future milestone for the director's compensation.

Industry Context

StockSavvy.ai notes that providing equity-based compensation to non-employee directors is a common practice across the medical technology and broader corporate sectors. This approach aims to align the interests of board members with long-term shareholder value creation, a standard in corporate governance.

Comparison to Industry Standards

• The structure of director compensation, combining equity awards and cash retainers (or equity in lieu of cash), is consistent with practices observed in leading medical device companies such as Medtronic plc and Abbott Laboratories, which also utilize restricted stock units or options to compensate their non-executive directors.
• The prorated nature of the awards for an initial appointment is a standard mechanism to ensure fair compensation based on the actual service period, mirroring policies seen in many S&P 500 companies.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The issuance of restricted stock results in a minor dilution but aims to align the director's long-term interests with shareholder value.
• Director (Christophe Pierre Weber): Receives compensation for board service, partially in equity, incentivizing performance aligned with the company's stock.

Next Steps

• The restricted stock grants will vest in full upon the date of Boston Scientific's 2026 annual meeting of stockholders.

Key Dates

Keywords

Boston Scientific, BSX, Form 4, Restricted Stock, Director Compensation, Equity Grant, Insider Transaction, Corporate Governance